Patent 12123880
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-flash
PTAB activity (1)
AIA trial proceedings — IPR, PGR, CBM — filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced directly from the PTAB Trial API.
- IPR2026-00168IPRfiled Dec 2, 2025vs. Sarepta Therapeutics, Inc. et al.Institution Denied
Cached for 24 hours. Status strings are sourced verbatim from the PTAB API; the colored badge is our heuristic classification.
Cases on file (1)
Group view →Specific litigation cases in our database that name US patent 12123880. The free-form analysis below may also discuss cases beyond this list.
- IPR2026-00168Patent Trial and Appeal Board (PTAB)Pending
Defendants: Genzyme Corp
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
As of April 26, 2026, known litigation involving US patent 12123880 includes one Inter Partes Review (IPR) proceeding before the Patent Trial and Appeal Board (PTAB).
Case Details:
- Case Number: IPR2026-00168 [cite: US12123880B2]
- Jurisdiction: Patent Trial and Appeal Board (PTAB) [cite: US12123880B2]
- Plaintiff(s)/Petitioner(s): Unified Patents [cite: US12123880B2]
- Defendant(s)/Patent Owner(s): Genzyme Corp [cite: US12123880B2]
- Filing Date: 2026 (implied by the case number IPR2026-00168). A more specific filing date is not available in the provided information.
- Outcome or Current Status: Pending [cite: US12123880B2]
No other litigation involving US patent 12123880 was found in the search results from CAFC or PACER.
Generated 5/27/2026, 12:47:15 PM